Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Volume 59(2); 2026 > Article
Review Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases
Ryu Ishiharaorcid
Clinical Endoscopy 2026;59(2):163-170.
DOI: https://doi.org/10.5946/ce.2025.208
Published online: March 3, 2026

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan

Correspondence: Ryu Ishihara Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan E-mail: ryu1486@gmail.com
• Received: June 28, 2025   • Revised: July 22, 2025   • Accepted: July 23, 2025

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 3,199 Views
  • 84 Download
next
  • Endoscopic resection (ER) is an established treatment for early stage esophageal squamous cell carcinoma. However, the management of non-curative resections remains a clinical challenge. This review aimed to evaluate the next steps for patients with non-curative resections based on the existing literature. Relevant studies on ER outcomes in esophageal squamous cell carcinoma, including recurrence rates, metastatic risks, and treatment strategies, were reviewed. The analysis focused on pathological findings, including tumor invasion depth and lymphovascular involvement (LVI). Comparative data on surgical resection and chemoradiotherapy (CRT) as adjuvant treatments were analyzed. Patients with pathological epithelial or lamina propria mucosa LVI-negative tumors showed low recurrence and metastasis rates (0.4%–5.6%). In contrast, those with submucosal or positive LVI cancer demonstrated a higher risk (10%–30%). Adjuvant treatment with surgery or CRT significantly reduced recurrence; however, the risk of complications must be considered. CRT showed favorable outcomes in low metastatic-risk cases, whereas surgery was preferred in high-risk patients. Active surveillance may be appropriate in certain low-risk patients with a poor overall health status. The management of non-curative ER cases requires individualized decision-making based on pathological risk factors. Further research is needed to refine the risk assessment and potentially utilize circulating tumor DNA testing to enhance precision.
Esophageal cancer is the seventh most frequent cancer and the seventh most common cause of cancer-related deaths globally, with an estimated 511,000 new cases and 445,000 deaths in 2022.1 The prognosis of patients with advanced-stage esophageal squamous cell carcinoma (ESCC) is generally poor. However, early stage ESCC can be cured via endoscopic resection (ER), esophagectomy, or chemoradiotherapy (CRT).2,3
The treatment strategy for early stage ESCC is primarily determined based on the preoperative assessment of the tumor invasion depth. However, the diagnostic accuracy for determining the tumor invasion depth in ESCC with ambiguous indications for ER remains suboptimal, ranging from 72% to 74%.4 Consequently, in current practice, ER is increasingly performed not only for lesions preoperatively judged as suitable for this approach but also for cases where the indication remains uncertain.5 As ER is applied to a broader range of lesions, the number of cases determined to be non-curative based on postoperative pathological findings has increased. Nevertheless, there has been insufficient investigation into the management of non-curative cases. Therefore, based on previous reports, this review examined how non-curative resection cases should be managed as the next step following ER.
Following ER for ESCC, a curability assessment is performed based on histopathological findings. This assessment involves evaluating the risk of metastatic recurrence determined by factors such as tumor invasion depth and lymphovascular involvement (LVI), as well as the risk of local recurrence, which is primarily assessed through the status of the resection margin. This section focuses primarily on the risk of metastatic recurrence. The evaluation of local recurrence risk and subsequent management strategies are addressed in a later section.
First, two reports described patients diagnosed with ESCC with invasion limited to the epithelium (pathological [p]EP) or lamina propria mucosa (pLPM), as well as LVI-negative based on pathological findings after ER.2,6 In one report, 280 patients with ESCC diagnosed with pEP/LPM had a metastatic recurrence rate of 0.4%.2 Another report observed 454 patients diagnosed with pEP/LPM LVI-negative cancers, with a 5-year disease-specific survival rate of 99.7%.6 These findings indicate that while the risk of metastatic recurrence or disease-specific mortality in pEP/LPM LVI-negative cancers is not entirely absent, it remains exceptionally low. Consequently, from the perspective of metastatic recurrence, such cases are likely to be curatively treated with ER alone. Therefore, current guidelines do not advocate additional treatment after ER for these cancers.7-11
For LVI-negative cancers invading the muscularis mucosa (pMM), studies evaluating the risk of metastasis using surgically resected specimens have reported metastatic risks ranging from 6.9% to 15.5%.12-15 In contrast, investigations into the risk of metastatic recurrence following ER for LVI-negative pMM cancers have demonstrated a lower frequency, with rates between 1.7% and 5.6%.9,16-18 The slice width of surgical specimens (5–7 mm) differs from that of ER specimens (2–3 mm).19,20 Histopathological assessment with a wider slice width (5–7 mm) of surgical specimens may have the risk of missing a small area of cancer invasion and a small amount of LVI, which can be detected with a thinner slice width (2–3 mm) of ER specimens. This difference may theoretically lead to different diagnoses between surgical specimens and ER specimens. Considering that the results of this investigation are expected to be applicable to decision-making after ER, an investigation using ER specimens is desirable. Given these findings, investigations using ER specimens are considered more relevant, suggesting a metastatic risk of approximately 1.7% to 5.6% based on such analyses. Current guidelines do not explicitly recommend whether additional treatments should be administered to this subset of patients. However, the past outcomes of adjuvant therapy indicate that recurrence occurs at a notable frequency, even with additional treatment (Table 1). Moreover, surgical resection or CRT, which are commonly employed as adjuvant therapies, carry the risk of treatment-related mortality and severe pulmonary complications.3 Therefore, post-ER surveillance without additional treatment may be a more reasonable approach for patients with pMM LVI-negative cancers who exhibit a lower recurrence risk than for those with submucosal (pSM) invasion or LVI-positive cancers.
Previous studies have reported a high risk of metastasis in pSM- and LVI-positive cancers.12,13,15,21-26 In contrast, a recent analysis evaluating the metastatic frequency based on tumor invasion depth on ER specimens and lymph node metastasis on surgical resection specimens confirmed that approximately 10% of pSM LVI-negative cancers and 30% of pSM LVI-positive cancers exhibited metastases (Table 2).27 As this study was based on the tumor invasion depth in ER specimens, it is likely to provide more relevant insights for predicting metastases following ER. According to these findings, the metastatic risk for pSM LVI-negative cancers and pMM/SM LVI-positive cancers was estimated to be 10% and 30%, respectively. Consequently, guidelines recommend additional treatment for these cancers to mitigate the metastatic risk.7-9,11
Among pSM- and LVI-positive cancers, distinct subgroups with varying metastatic risks exist (Table 2), necessitating appropriate management based on their respective risk profiles. Numerous studies have investigated the factors associated with metastatic risk in T1 ESCC (Table 3).12,22,28-34 These reports have frequently identified tumor invasion depth, LVI, lesion size, and tumor differentiation as risk factors for metastasis. However, while Japanese studies similarly highlighted tumor invasion depth, LVI, and lesion size as significant risk factors, tumor differentiation has not been consistently identified.12,22,29 This discrepancy is likely attributable to differences in the evaluation of tumor differentiation in Japan, where assessments are conducted based on the degree of keratinization,19 in contrast to the criteria outlined in the World Health Organization classification.
Next, as previously mentioned, studies utilizing surgical resection specimens may yield different assessments of tumor invasion depth than those based on ER specimens. Therefore, we introduced a study that employed ER specimens, which may be more applicable in clinical practice.35 In this study, histopathological findings, such as tumor invasion depth and LVI, were comprehensively evaluated using ER specimens. The presence or absence of metastases was determined through post-ER follow-up analysis. The relationship between the histopathological findings and metastases was subsequently examined. This study identified significant predictors of metastasis, including LVI and tumor invasion depth, using multivariate analysis. Conversely, no association was observed between metastasis and lesion size, differentiation, cytological atypia, or the infiltration pattern. Droplet infiltration (≥4) (Fig. 1), an indicator of the infiltration pattern, was identified as an independent and strong predictor of LVI. A review of previous reports suggests that tumor invasion depth and LVI are likely to be closely associated with metastatic risk. Additionally, infiltration patterns may be strongly correlated with LVI and may indirectly contribute to metastasis. However, the findings related to other pathological factors remain controversial.
In daily clinical practice, decisions regarding the need for additional treatment after ER must be made based on the metastatic risk factors outlined thus far. When additional treatment is deemed necessary, an optimal therapeutic approach should be carefully considered. For T1 ESCC with regional lymph node metastases, surgical resection and CRT are recognized as curative treatment options. Previously, surgical resection was the primary modality used as adjuvant therapy to reduce the risk of metastatic recurrence after ER. However, since the 1990s, CRT has been increasingly used as the definitive treatment for ESCC in Japan. Owing to its less invasive nature compared to surgical resection, CRT has gradually been adopted as an adjuvant treatment following ER. In 2005, the JCOG0508 trial was initiated to evaluate the efficacy of CRT as adjuvant therapy following ER.5,36 This trial demonstrated favorable outcomes, with a 5-year survival rate of 89.7% after ER and CRT. Consequently, CRT was incorporated into clinical guidelines as a viable option for adjuvant treatment after ER.7,9
Several studies have compared surgical resection and CRT after ER. A review summarizing these studies suggested that for patients with high-risk cancers, such as pSM LVI-positive cancers, surgical resection may offer a slight advantage over CRT.37-42 However, it has been well documented that patients receiving CRT tend to be older, have a worse overall health status, and have more comorbidities than do those undergoing surgical resection. These factors introduce a significant bias when comparing the two treatment options. Notably, previous comparative studies have not accounted for these variables. To address this, we conducted a study using patient data from 62 Japanese institutions. We selected patients diagnosed with pMM LVI-positive cancers or SM cancers based on post-ER histopathological findings who subsequently underwent either surgical resection or CRT as additional treatment. Propensity score matching was used to compare the efficacies of the two interventions (Table 1).43
This study found no significant differences in the overall survival (OS) or progression-free survival (PFS) rates between surgical resection and CRT in the overall cohort, suggesting comparable efficacy. However, among patients with high-risk pSM LVI-positive cancers, surgical resection demonstrated a modest advantage in terms of OS and PFS (hazard ratios, 1.41 [0.71–2.83] for OS and 1.50 [0.79–2.83] for PFS). Conversely, in patients with lower metastatic risk, such as those with pSM LVI-negative cancers or pMM LVI-positive cancers, CRT showed a slight advantage (hazard ratios, 0.56 [0.27–1.16] for OS and 0.66 [0.34–1.28] for PFS). Although the differences were not statistically significant, the hazard ratios deviated from 1, indicating a potential clinical relevance that could inform treatment decisions. Based on these results, the authors recommended surgical resection for patients with high-risk pSM LVI-positive cancers, while advising CRT for patients with lower-risk pSM LVI-negative cancers or pMM LVI-positive cancers. However, given the retrospective nature of this study, the findings may be subject to bias. Currently, a randomized trials comparing surgical resection with CRT as an adjuvant treatment after ER, Ad-ESD Trial44 and ASSURE Trial, are underway in China and Korea, and their results are anticipated to offer critical insights for determining the optimal post-endoscopic treatment strategy.
As previously noted, if additional treatment is not performed in cases of non-curative ER, recurrence is expected in 10% to 30% of cases.27 Therefore, additional treatments were recommended. However, certain cases present challenges for further intervention owing to advanced age or compromised overall health status. Even when additional treatment is viable, concerns regarding a potential decline in the quality of life (QOL) may arise. The prognosis of patients managed with observation alone without subsequent therapy remains a pertinent clinical question. Two studies offered valuable insights into this issue.
The first study analyzed 386 cases of superficial ESCC without additional treatment after ER. The patients were stratified into low-(pMM/SM1 LVI-negative), intermediate-(pMM LVI-positive or pSM2 LVI-negative), and high-risk (pSM LVI-positive) groups. The disease-specific survival rates at 5 years were 99.6%, 94.0%, and 79.7%, respectively.18 The second report examined 64 cases of superficial ESCC, classified as pMM or deeper, that were observed without additional treatment. The OS rate did not differ from that of 48 patients who received additional treatment (p=0.686).6 These findings suggest that observation without additional treatment is a promising therapeutic approach. However, as these results were derived from retrospective studies, the treatment outcomes may be subject to various biases. Well-designed prospective studies are necessary to confirm whether observation after ER with treatment initiated at the time of recurrence yields results comparable to those of immediate additional treatment following ER.
During the era when endoscopic mucosal resection was the primary ER method, larger lesions were often removed piecemeal. The number of piecemeal resections has been reported to correlate with the risk of residual or recurrent disease,45 with residual or recurrent lesions observed in approximately half of the cases involving five or more fragments. However, with the widespread adoption of endoscopic submucosal dissection (ESD), piecemeal resection has become rare.
Two studies investigated the relationship between horizontal margins and residual or recurrent disease after en bloc resection via ESD. In one study, 70 lesions with circumferential involvement exceeding half of the esophageal circumference were resected as closely as possible to reduce the risk of post-ESD strictures, and the incidence of residual or recurrent disease was evaluated. Of the 70 patients, 27 had positive or indeterminate lateral margins; however, none exhibited residual or recurrent disease. Conversely, another study examined 39 patients with positive or indeterminate lateral margins for various reasons, revealing residual or recurrent disease in 40.0% (6/15) of the patients with positive margins and 13.3% (2/15) of the patients with indeterminate margins. Among the eight patients with residual lesions, six were treated with additional ER, while the remaining two underwent radiotherapy or CRT. None of the patients developed lymph node or distant metastases. These findings suggest that when the horizontal margin is classified as pathological horizontal margin cannot be assessed (pHMX) or pathological horizontal margin positive (pHM1), careful observation is warranted to monitor local recurrence. However, if the lesion is accurately diagnosed and intentionally resected at the margins, the risk of local recurrence in cases classified as pHMX or pHM1 is low.
Regarding the relationship between vertical margins and local residual or recurrent disease, the following report evaluated cases of pMM and pSM cancers.27 In this study, local residual cancer was detected in 16 of the 222 patients (7.2%). Among the cases classified as pathological vertical margin cannot be assessed (pVMX) or pathological vertical margin positive (pVM1), local recurrence was observed in 10 of the 52 cases (19.2%), with 80% of these involving the submucosal or deeper layers. In cases of VM0, local residual cancer was observed in 6 of 170 cases (3.5%), of which 66.7% were mucosal cancers. However, in two cases classified as pathological vertical margin negative (pVM0), the cancer persisted in the submucosal or deeper layers. The rate of local residual disease was 16.7% (2/12) for pVMX and 20.0% (8/40) for pVM1, with no significant intergroup difference. Post-resection histopathological findings indicated that pMM or pSM cancers with pVMX or pVM1 were associated with a high risk of local recurrence, with the majority occurring in the submucosal or deeper layers, warranting additional prophylactic treatment. Conversely, even in cases classified as pVM0, rare instances of submucosal or deeper residual cancer may occur, necessitating careful observation if no additional treatment is administered.
Currently, the treatment strategy after ER is determined based on the histopathological findings of ER specimens. However, this assessment does not provide a direct evaluation of the residual cancer cells and has limited accuracy. As a result, unnecessary additional treatments may be administered to patients who do not experience recurrence, whereas those at a genuine risk of recurrence may not receive appropriate therapeutic intervention, leading to poor outcomes. To improve the accuracy of predicting the risk of metastatic recurrence and ensure that only patients who truly need additional treatment receive it, a direct examination of residual cancer cells is necessary in patients who have undergone ER. Among the available methods for confirming the presence or absence of cancer cells, circulating tumor DNA (ctDNA) testing, which has been clinically applied to other cancers, is considered the most promising.46,47 For example, ctDNA has been reported to predict the need for adjuvant chemotherapy after surgical resection of colorectal cancer.48 If a similar approach could be applied to ESCC, additional selective treatments could be performed.
Furthermore, in terms of treatment, studies have demonstrated that DCF therapy (docetaxel, cisplatin, and 5-fluorouracil)49 and immune checkpoint inhibitors50 can significantly improve treatment outcomes. Implementation of more intensive therapies may enhance the likelihood of achieving curative outcomes, even in cases where metastatic recurrence is identified after ER. In the future, there may be a shift toward rigorous surveillance for metastatic recurrence without additional treatment immediately after ER. In this model, curative treatment is initiated only upon detection of recurrence using advanced technology, thereby minimizing overtreatment while ensuring aggressive intervention when warranted.
The optimal treatment strategy for patients after ER remains an area of ongoing research. Presently, the treatment approach requires precise histopathological evaluation of resected specimens, with risk assessment for metastases predicated on factors such as tumor invasion depth and vascular involvement. However, this approach is not optimal. Future advancements should focus on developing techniques to directly assess the presence of residual cancer cells after ER. By reserving intensive therapeutic interventions for patients with confirmed residual malignancy, treatment efficacy and QOL can be substantially enhanced.
Fig. 1.
Droplet infiltration, defined as a small (no more than four cancer cells) cancer cell cluster with droplet-like morphology that is distinctly separate from the main tumor (yellow arrows).
ce-2025-208f1.jpg
Table 1.
Outcome of additional treatment after ER
Esophagectomy (% or % [n/total n]) CRT (% or % [n/total n]) HR (95% CI) for CRT
5-Year OS
 All patients 89.1 90.0 0.89 (0.54–1.45)
 High-risk patients 84.5 82.6 1.41 (0.71–2.83)
 Low-risk patients 92.3 94.5 0.56 (0.27–1.16)
5-Year PFS
 All patients 83.7 86.6 1.04 (0.66–1.62)
 High-risk patients 79.8 81.0 1.50 (0.79–2.83)
 Low-risk patients 86.6 91.0 0.66 (0.34–1.28)
Metastatic recurrence
 All patients 9.4 (15/160) 12.5 (20/160) NA
 High-risk patients 13.4 (9/67) 17.9 (12/67) NA
 Low-risk patients 6.5 (6/93) 8.6 (8/93) NA

ER, endoscopic resection; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; high-risk patients, submucosa cancer with lymphovascular invasion; low-risk patients; muscularis mucosa cancer with lymphovascular invasion or submucosa cancer without lymphovascular invasion; NA, not assessed.

Based on ref. 43

Table 2.
Incidence of metastasis with regard to invasion depth and lymphovascular invasion27
Retrospective study using esophagectomy and follow-up data Metastasis rate (% [n/total n patients])
SM1, LVI– 8.0 (2/25)
SM2, LVI– 9.4 (3/32)
MM, LVI+ 25.7 (9/35)
SM1, LVI+ 32.3 (10/31)
SM2, LVI+ 27.7 (13/47)
VMX or 1, LVI– 20 (3/15)
VMX or 1, LVI+ 35.1 (13/37)

SM, submucosa; LVI, lymphovascular invasion; MM, muscularis mucosa; VMX, residual tumor in the vertical margin cannot be assessed.

Adapted from Ishihara, et al. Dig Endosc 2025 Jul 6 [Epub]. https://doi.org/10.1111/den.15082, with permission.27

Table 3.
Risk factors of metastasis
Study Country Subject Risk factors of metastasis
Duan et al.28 China M, 50; SM, 93 cancer invasion depth, lesion size, location, differentiation
Kadota et al.22 Japan SM, 108 cancer invasion depth, LVI, lesion size
Zhou et al.30 China M, 160; SM, 338 cancer invasion depth, LVI, lesion size, differentiation
Qi et al.31 China SM, 258 LVI, tumor volume
Li et al.32 China M, 47; SM, 142 cancer invasion depth, LVI
Xue et al.33 China M, 52; SM, 219 cancer invasion depth, EGFR, VEGF
Kim et al.34 Korea M, 64; SM, 133 lesion size, LVI, macroscopic type
Shimada et al.29 Japan M, 37; SM, 123 Lymphatic invasion, intramural meta
Eguchi et al.12 Japan M, 100; SM, 364 Cancer invasion depth, LVI

M, mucosal cancer; SM, submucosal cancer; LVI, lymphovascular invasion; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.

  • 1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–263.ArticlePubMed
  • 2. Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol 2013;108:544–551.ArticlePubMedPDF
  • 3. Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 2021;161:1878–1886.ArticlePubMed
  • 4. Ishihara R, Mizusawa J, Kushima R, et al. Assessment of the diagnostic performance of endoscopic ultrasonography after conventional endoscopy for the evaluation of esophageal squamous cell carcinoma invasion depth. JAMA Netw Open 2021;4:e2125317.ArticlePubMedPMC
  • 5. Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. Gastroenterology 2019;157:382–390.ArticlePubMed
  • 6. Iwai N, Dohi O, Yamada S, et al. Prognostic risk factors associated with esophageal squamous cell carcinoma patients undergoing endoscopic submucosal dissection: a multi-center cohort study. Surg Endosc 2022;36:2279–2289.ArticlePubMedPDF
  • 7. Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 1. Esophagus 2023;20:343–372.ArticlePubMedPMCPDF
  • 8. Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus 2023;20:373–389.ArticlePubMedPMCPDF
  • 9. Ishihara R, Arima M, Iizuka T, et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 2020;32:452–493.ArticlePubMedPDF
  • 10. Pimentel-Nunes P, Libânio D, Bastiaansen BA, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) guideline: update 2022. Endoscopy 2022;54:591–622.ArticlePubMed
  • 11. Park CH, Yang DH, Kim JW, et al. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Clin Endosc 2020;53:142–166.ArticlePubMedPMCPDF
  • 12. Eguchi T, Nakanishi Y, Shimoda T, et al. Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol 2006;19:475–480.ArticlePubMedPDF
  • 13. Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg 2013;257:1032–1038.ArticlePubMed
  • 14. Egashira H, Yanagisawa A, Kato Y. Predictive factors for lymph node metastasis in esophageal squamous cell carcinomas contacting or penetrating the muscularis mucosae: the utility of droplet infiltration. Esophagus 2006;3:47–52.ArticlePDF
  • 15. Min BH, Yang JW, Min YW, et al. Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. J Gastroenterol Hepatol 2020;35:1009–1015.ArticlePubMedPDF
  • 16. Sato D, Kadota T, Inaba A, et al. Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion. Gastrointest Endosc 2022;95:634–641.ArticlePubMed
  • 17. Naito S, Yoshio T, Ishiyama A, et al. Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment. Dig Endosc 2022;34:793–804.ArticlePubMedPDF
  • 18. Hatta W, Koike T, Takahashi S, et al. Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study. J Gastroenterol 2021;56:620–632.ArticlePubMedPDF
  • 19. Doki Y, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: part II. Esophagus 2024;21:216–269.ArticlePubMedPMCPDF
  • 20. Mine S, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: part I. Esophagus 2024;21:179–215.ArticlePubMedPMCPDF
  • 21. Emi M, Hihara J, Hamai Y, et al. Clinicopathologic features of submucosal esophageal squamous cell carcinoma. Ann Thorac Surg 2017;104:1858–1864.ArticlePubMed
  • 22. Kadota T, Yano T, Fujita T, et al. Submucosal invasive depth predicts lymph node metastasis and poor prognosis in submucosal invasive esophageal squamous cell carcinoma. Am J Clin Pathol 2017;148:416–426.ArticlePubMed
  • 23. Xu W, Liu XB, Li SB, et al. Prediction of lymph node metastasis in superficial esophageal squamous cell carcinoma in Asia: a systematic review and meta-analysis. Dis Esophagus 2020;33:doaa032.ArticlePubMedPDF
  • 24. Jiang KY, Huang H, Chen WY, et al. Risk factors for lymph node metastasis in T1 esophageal squamous cell carcinoma: a systematic review and meta-analysis. World J Gastroenterol 2021;27:737–750.ArticlePubMedPMC
  • 25. Tajima Y, Nakanishi Y, Ochiai A, et al. Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma: analysis of 240 surgically resected tumors. Cancer 2000;88:1285–1293.ArticlePubMed
  • 26. Akutsu Y, Kato K, Igaki H, et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg 2016;264:1009–1015.ArticlePubMed
  • 27. Ishihara R, Kawakubo H, Yamamoto Y, et al. Risk of metastasis and local residual cancer after non-curative endoscopic submucosal dissection for esophageal cancer. Dig Endosc 2025 Jul 6 [Epub]. https://doi.org/10.1111/den.15082Article
  • 28. Duan X, Shang X, Yue J, et al. A nomogram to predict lymph node metastasis risk for early esophageal squamous cell carcinoma. BMC Cancer 2021;21:431.ArticlePubMedPMCPDF
  • 29. Shimada H, Nabeya Y, Matsubara H, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006;191:250–254.ArticlePubMed
  • 30. Zhou Y, Du J, Li H, et al. Clinicopathologic analysis of lymph node status in superficial esophageal squamous carcinoma. World J Surg Oncol 2016;14:259.ArticlePubMedPMCPDF
  • 31. Qi X, Li M, Zhao S, et al. Prevalence of metastasis in T1b esophageal squamous cell carcinoma: a retrospective analysis of 258 Chinese patients. J Thorac Dis 2016;8:966–976.ArticlePubMedPMC
  • 32. Li B, Chen H, Xiang J, et al. Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2013;146:1198–1203.ArticlePubMed
  • 33. Xue L, Ren L, Zou S, et al. Parameters predicting lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. Mod Pathol 2012;25:1364–1377.ArticlePubMedPMCPDF
  • 34. Kim DU, Lee JH, Min BH, et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. J Gastroenterol Hepatol 2008;23:619–625.ArticlePubMed
  • 35. Ishihara R, Kawachi H, Nakano K, et al. Comprehensive pathological evaluation of risk factors for metastasis after endoscopic resection of superficial esophageal squamous cell carcinoma. J Gastroenterol 2025;60:131–140.ArticlePubMedPDF
  • 36. Nihei K, Minashi K, Yano T, et al. Final analysis of diagnostic endoscopic resection followed by selective chemoradiotherapy for stage I esophageal cancer: JCOG0508. Gastroenterology 2023;164:296–299.ArticlePubMed
  • 37. Li J, Wang L, Shi X, et al. Therapeutic strategies following endoscopic submucosal dissection for T1a-MM/T1b-SM1 esophageal squamous cell carcinoma: comparisons of long-term outcomes with propensity score-matched analysis. Surg Endosc 2023;37:1761–1770.ArticlePubMedPDF
  • 38. Suzuki G, Yamazaki H, Aibe N, et al. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach. Radiat Oncol 2018;13:246.ArticlePubMedPMCPDF
  • 39. Tanaka T, Ueno M, Iizuka T, et al. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma. Dis Esophagus 2019;32:doz023.ArticlePubMedPDF
  • 40. Koterazawa Y, Nakamura T, Oshikiri T, et al. A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy after noncurative endoscopic submucosal dissection for esophageal squamous cell carcinoma. Surg Today 2018;48:783–789.ArticlePubMedPMCPDF
  • 41. Ikeda A, Hoshi N, Yoshizaki T, et al. Endoscopic submucosal dissection (ESD) with additional therapy for superficial esophageal cancer with submucosal invasion. Intern Med 2015;54:2803–2813.ArticlePubMed
  • 42. Tsou YK, Lee CH, Le PH, et al. Adjuvant therapy for pT1a-m3/pT1b esophageal squamous cell carcinoma after endoscopic resection: Esophagectomy or chemoradiotherapy?: a critical review. Crit Rev Oncol Hematol 2020;147:102883.ArticlePubMed
  • 43. Yamamoto Y, Ishihara R, Kawakubo H, et al. Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study. J Gastroenterol 2025;60:43–54.ArticlePubMedPDF
  • 44. Yang Y, Su Y, Zhang X, et al. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial). Trials 2020;21:603.ArticlePubMedPMCPDF
  • 45. Ishihara R, Iishi H, Takeuchi Y, et al. Local recurrence of large squamous-cell carcinoma of the esophagus after endoscopic resection. Gastrointest Endosc 2008;67:799–804.ArticlePubMed
  • 46. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985–990.ArticlePubMedPMCPDF
  • 47. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715–1722.ArticlePubMedPMC
  • 48. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29:127–134.ArticlePubMedPMCPDF
  • 49. Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 2024;404:55–66.ArticlePubMed
  • 50. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386:449–462.ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases
        Clin Endosc. 2026;59(2):163-170.   Published online March 3, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      Related articles
      Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases
      Image
      Fig. 1. Droplet infiltration, defined as a small (no more than four cancer cells) cancer cell cluster with droplet-like morphology that is distinctly separate from the main tumor (yellow arrows).
      Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases
      Esophagectomy (% or % [n/total n]) CRT (% or % [n/total n]) HR (95% CI) for CRT
      5-Year OS
       All patients 89.1 90.0 0.89 (0.54–1.45)
       High-risk patients 84.5 82.6 1.41 (0.71–2.83)
       Low-risk patients 92.3 94.5 0.56 (0.27–1.16)
      5-Year PFS
       All patients 83.7 86.6 1.04 (0.66–1.62)
       High-risk patients 79.8 81.0 1.50 (0.79–2.83)
       Low-risk patients 86.6 91.0 0.66 (0.34–1.28)
      Metastatic recurrence
       All patients 9.4 (15/160) 12.5 (20/160) NA
       High-risk patients 13.4 (9/67) 17.9 (12/67) NA
       Low-risk patients 6.5 (6/93) 8.6 (8/93) NA
      Retrospective study using esophagectomy and follow-up data Metastasis rate (% [n/total n patients])
      SM1, LVI– 8.0 (2/25)
      SM2, LVI– 9.4 (3/32)
      MM, LVI+ 25.7 (9/35)
      SM1, LVI+ 32.3 (10/31)
      SM2, LVI+ 27.7 (13/47)
      VMX or 1, LVI– 20 (3/15)
      VMX or 1, LVI+ 35.1 (13/37)
      Study Country Subject Risk factors of metastasis
      Duan et al.28 China M, 50; SM, 93 cancer invasion depth, lesion size, location, differentiation
      Kadota et al.22 Japan SM, 108 cancer invasion depth, LVI, lesion size
      Zhou et al.30 China M, 160; SM, 338 cancer invasion depth, LVI, lesion size, differentiation
      Qi et al.31 China SM, 258 LVI, tumor volume
      Li et al.32 China M, 47; SM, 142 cancer invasion depth, LVI
      Xue et al.33 China M, 52; SM, 219 cancer invasion depth, EGFR, VEGF
      Kim et al.34 Korea M, 64; SM, 133 lesion size, LVI, macroscopic type
      Shimada et al.29 Japan M, 37; SM, 123 Lymphatic invasion, intramural meta
      Eguchi et al.12 Japan M, 100; SM, 364 Cancer invasion depth, LVI
      Table 1. Outcome of additional treatment after ER

      ER, endoscopic resection; CRT, chemoradiotherapy; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; high-risk patients, submucosa cancer with lymphovascular invasion; low-risk patients; muscularis mucosa cancer with lymphovascular invasion or submucosa cancer without lymphovascular invasion; NA, not assessed.

      Based on ref. 43

      Table 2. Incidence of metastasis with regard to invasion depth and lymphovascular invasion27

      SM, submucosa; LVI, lymphovascular invasion; MM, muscularis mucosa; VMX, residual tumor in the vertical margin cannot be assessed.

      Adapted from Ishihara, et al. Dig Endosc 2025 Jul 6 [Epub]. https://doi.org/10.1111/den.15082, with permission.27

      Table 3. Risk factors of metastasis

      M, mucosal cancer; SM, submucosal cancer; LVI, lymphovascular invasion; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.


      Clin Endosc : Clinical Endoscopy Twitter Facebook
      Close layer
      TOP